UBS AM’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

UBS AM’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,448	Closed	-$1.98M	–	2743
2023 Q2	$1.98M	Hold	18,448	–	–	﹤0.01%	1648
2023 Q1	$1.98M	Sell	18,448 -76	-0.4%	-$8.75K	﹤0.01%	1648
2022 Q4	$2.04M	Buy	18,524 +12,324	+199%	+$799K	﹤0.01%	1514
2022 Q3	$366K	Buy	+6,200	New	+$284K	﹤0.01%	2448
2022 Q2	–	Sell	-6,200	Closed	-$234K	–	2810
2022 Q1	$234K	Buy	+6,200	New	+$245K	﹤0.01%	2647

UBS AM's RXDX Position: Q3 2023 in Review

UBS AM sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q3 2023, closing a stake of 18,448 shares — an estimated $1.98M sold.

UBS AM first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $2.04M in Q4 2022. 0 funds tracked by Wall St. Rank hold RXDX as of Q3 2023.

UBS AM reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS AM sold 18,448 Prometheus Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $1.98M.
UBS AM first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
UBS AM's Prometheus Biosciences, Inc. Common Stock position peaked at $2.04M in Q4 2022.
0 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.